Seventy-three varieties conform to the fourth batch

Recently, the State Bureau has accelerated the approval speed of generic consistent evaluation, especially injections, in a short period of time, a number of varieties that meet the conditions of the collection (i.e., the original research ≥3), from the first evaluation to meet the conditions of the collection of only the first line.Previously, the Health Insurance Bureau in the future collection also named biological products (including insulin), Chinese medicine, the number of varieties eligible for collection conditions or its amount reached a certain level, that is, trigger the start of national harvesting, is expected to carry out two batches per year. According to previously disclosed information, the fourth batch of harvesting has been getting closer: the collection of varieties has been screened.From the third batch of national organizations drug collection progress inference, there are industry analysis, the next round of collection or is expected to start early next year. According to the network information, Tuesday will be held a drug collection symposium, which may also be one of the signs of the fourth batch of collection approaching.Currently, according to the Insight database consistency evaluation module, as of December 4, 67 chemical drug species are eligible for harvesting, and there are more than 3 insulin and 3 biosynthic drug companies. Two of the 32 varieties have been reviewed and have companies under review, which are also potential targets. Details of varieties that meet the collection are attached to the end of the text.From the dimension of dosage form, the varieties that meet the requirements of the collection are still mainly chemical drugs, but with the acceleration of the review of the supplementary application for injections by the State Bureau, the proportion of injections in the collection will gradually increase, especially the high sales volume, full market competition of large varieties of injections.In terms of enterprise dimension, 10 enterprises have met the requirements of the collection of generic drugs has reached more than 5 varieties, of which China biopharmaceuticals as the most, there are 11 generic drugs full of 3; Among foreign companies, Grigg Ingham, Pfizer, Novarma and Mercedon are the most involved.As for biological drugs, at present, Adamu single resistance has been approved in China, Fuhong Hanxuan has also entered the administrative approval stage, is about to become the 5th; 3 insulin (recombinant human insulin injection, sperm protein recombinant human insulin injection, insulin glycerin) have also been approved in China has also met 3. (
Insight database
)